2 345

Cited 44 times in

Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer

Authors
 Moon Jae Chung  ;  Jeong Youp Park  ;  Seungmin Bang  ;  Seung Woo Park  ;  Si Young Song 
Citation
 CANCER IMMUNOLOGY IMMUNOTHERAPY, Vol.63(9) : 939-946, 2014 
Journal Title
 CANCER IMMUNOLOGY IMMUNOTHERAPY 
ISSN
 0340-7004 
Issue Date
2014
MeSH
Adenocarcinoma/immunology ; Adenocarcinoma/therapy ; Adult ; Aged ; Cytokine-Induced Killer Cells/immunology* ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods* ; Male ; Middle Aged ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/therapy* ; Quality of Life ; Treatment Outcome
Keywords
Adoptive immunotherapy ; Cytokine-induced killer cells ; Gemcitabine refractory ; Pancreatic cancer
Abstract
Second-line chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer has shown disappointing survival outcomes due to rapid disease progression and performance deterioration. The aim of this phase II trial was to evaluate the efficacy and safety of adoptive immunotherapy using ex vivo-expanded, cytokine-induced killer (CIK) cells in gemcitabine-refractory advanced pancreatic cancer. Patients with advanced pancreatic cancer who showed disease progression during gemcitabine-based chemotherapy were enrolled in this study. For generation of CIK cells, peripheral blood samples were collected from each patient and cultured with anti-CD3 monoclonal antibody and IL-2. Patients received CIK cells intravenously 10 times, every week for 5 weeks and then every other week for 10 weeks. Twenty patients were enrolled between November 2009 and September 2010. The disease control rate was 25 % (4/16 patients). The median progression-free survival (PFS) was 11.0 weeks (95 % CI 8.8–13.2), and the median overall survival (OS) was 26.6 weeks (95 % CI 8.6–44.6). Grade 3 toxicities included general weakness in two patients and thrombocytopenia in one patient. Grade 4 hematologic or non-hematologic toxicity was not observed. Patients showed improvement in pancreatic pain, gastrointestinal distress, jaundice, body image alterations, altered bowel habits, health satisfaction, and sexuality when assessing quality of life (QoL). Adoptive immunotherapy using CIK cells showed comparable PFS and OS to survival data of previous trials that assessed conventional chemotherapies while maintaining tolerability and showing encouraging results in terms of patient QoL in gemcitabine-refractory advanced pancreatic cancer (clinicalTrials.gov number NCT00965718).
Full Text
http://link.springer.com/article/10.1007%2Fs00262-014-1566-3
DOI
10.1007/s00262-014-1566-3
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Chung, Moon Jae(정문재) ORCID logo https://orcid.org/0000-0002-5920-8549
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/99646
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse